Results 161 to 170 of about 31,062 (287)

Correction to ‘Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population’

ESC Heart Failure, Volume 12, Issue 2, Page 1523-1523, April 2025.
wiley   +1 more source

Impact of early intensive GDMT on LVEF recovery and ICD decision making in de novo HFrEF

ESC Heart Failure, EarlyView.
Abstract Aims Implantable cardioverter‐defibrillator (ICD) implantation is recommended in patients with heart failure with reduced ejection fraction (HFrEF) and left ventricular ejection fraction (LVEF) ≤ 35% after 3 months of optimized medical therapy (OMT).
Diogo Rosa Ferreira, Daniel Inácio Cazeiro, Joana Brito, Rafael Santos, Joana Rigueira, Doroteia Silva, Nuno Lousada, Fausto Pinto, Dulce Brito, João Agostinho   +9 more
wiley   +1 more source

Evaluation of the Effects of the Sodium–Glucose Cotransporter 2 Inhibitors and Sacubitril/Valsartan Combined Therapy in Patients with HFrEF: An Echocardiographic Study [PDF]

Isabella Fumarulo, Annalisa Pasquini, Giulia La Vecchia, Bianca Pellizzeri, Andriy Sten, Barbara Garramone, Marcello Vaccarella, Salvatore Emanuele Ravenna, Antonella Lombardo, Francesco Burzotta, Dario Pitocco, Nadia Aspromonte   +11 more
openalex   +1 more source

Long‐term prognosis of pure and impure tachycardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Background and aims Tachycardia‐induced cardiomyopathy (TCM) is a reversible form of heart failure (HF) driven by arrhythmias, often atrial fibrillation (AF). While reversible, TCM's long‐term prognosis remains unclear, especially in comparison to HF with reduced ejection fraction (HFrEF).
Giulia Stronati, Michele Alfieri, Niki Tombolesi, Alessandro Barbarossa, Samuele Principi, Federico Gullì, Arianna Massari, Gianmarco Bastianoni, Francesca Roccetti, Michela Casella, Antonio Dello Russo, Federico Guerra   +11 more
wiley   +1 more source

HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study. [PDF]

Cardiovasc Diabetol
Gil-Millan P, Gimeno-Orna JA, Rodriguez-Padial L, Muniz J, Barrios V, Anguita M, Perez A.   +6 more
europepmc   +1 more source

Updated guidance from NICE on implantable defibrillators: does it work in real life? [PDF]

, 2016
Cowie, MR
core   +1 more source

The association between polypharmacy and mortality in patients with heart failure: Results from the PULSE dataset

ESC Heart Failure, EarlyView.
A study of 660 heart failure patients (mean age 76.1) found that polypharmacy was common, with only 5% discharged without it, and 60% had died by the end of a median 2.9‐year follow‐up. In patients with heart failure with reduced ejection fraction (HFrEF), hyperpolypharmacy was associated with significantly higher mortality, while in those with ...
Janine Beezer, Andrew L. Clark, Adam Todd, Andrew Kingston, Andrew Husband   +4 more
wiley   +1 more source

Dietary Nitrate Prevents Cardiac Dysfunction in HFrEF by Improving Hemodynamics, Ameliorating Remodeling, and Resolving Inflammation. [PDF]

Acta Physiol (Oxf)
Shimari M, Picozzi G, Boeder A, Guimarães DD, Zhuge Z, Lundberg JO, Carlstrom M, Lund LH, Andersson DC, Pironti G.   +9 more
europepmc   +1 more source

Incidence and determinants of left ventricular ejection fraction (LVEF) recovery in heart failure with reduced ejection fraction (HFrEF) of non-ischemic aetiology; a hospital-based prospective longitudinal registry study

Sanjeev Kumar, Prakash Chand Negi, Sanjeev Asotra, Jitender Kumar, Rajeev Merwah, Rajesh Sharma, Ritesh Kumar, Vinay Bhardwaj, Pradeep Kumar Thakur   +8 more
openalex   +1 more source

Finerenone vs eplerenone for patients with HFrEF [PDF]

, 2016
Karina Huynh
openalex   +1 more source